ÐÂÎÅÖÐÐÄ
News Center
¾ºÖðÐÂÐ˰еãFGFR2b£¡£¡ÖйúÉúÎïÖÆÒ©ÇÀռȫÇòÁÙ´²Ö÷Ҫϯλ
Ðû²¼Ê±¼ä£º£º£º2025-03-26
¿ËÈÕ£¬£¬£¬ÖйúÉúÎïÖÆÒ©£¨1177.HK£©ÏÂÊôÆóÒµÕý´óÌìÇç×ÔÖ÷Ñз¢µÄ1ÀàÁ¢ÒìÒ©TQB2210×¢ÉäÒº£¬£¬£¬Ê״λñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©ÁÙ´²ÊÔÑéÅú×¼£¬£¬£¬ÄâÓÃÓÚÖÎÁÆÍíÆÚ¶ñÐÔÖ×Áö¡£×÷Ϊ¡¶ÓÅ»¯Á¢ÒìÒ©ÁÙ´²ÊÔÑéÉóÆÀÉóÅúÊÔµãÊÂÇé·½°¸¡·µÄÊÔµãÏîÄ¿£¬£¬£¬¸ÃÒ©ÁÙ´²ÉóÆÀÖÜÆÚËõ¶ÌÖÁ30¸öÊÂÇéÈÕ¡£È«Çò¹æÄ£ÄÚÉÐδÓÐͬ°ÐµãÒ©ÎïÉÏÊС£
TQB2210ÊÇÒ»¿î°ÐÏòFGFR2bµÄÈËÔ´»¯µ¥¿Ë¡¿¹Ì壬£¬£¬Í¨¹ý×è¶Ï³ÉÏËάϸ°ûÉú³¤Òò×ÓÊÜÌå½éµ¼µÄÐźÅͨ·ÒÖÖÆÖ×ÁöÉú³¤£¬£¬£¬²¢Í¨¹ýÆäFc½éµ¼µÄ¿¹ÌåÒÀÀµÐÔϸ°û½éµ¼µÄϸ°û¶¾ÐÔ×÷Óã¨ADCC£©É±ÉËÖ×Áöϸ°û¡£FGFR2bµÄ¹ý±í´ïÓëθ°©¡¢¡¢ÈéÏÙ°©¡¢¡¢¸ÎÄÚµ¨¹Ü°©µÈ¸ßÇÖÏ®ÐÔÖ×ÁöÇ×½üÏà¹Ø[1-4]£¬£¬£¬Ô¼30%µÄHER2ÒõÐÔÍíÆÚθ°©»¼ÕßÖб£´æFGFR2b¹ý±í´ï[5]¡£Î¸°©ÊÇÎÒ¹ú¸ß·¢°©Ö¢Ö®Ò»£¬£¬£¬¿ª·¢°ÐÏòFGFR2bµÄÖÎÁÆ·½°¸£¬£¬£¬ÓÐÖúÓÚÍƽø»ùÓÚÉúÎï±ê¼ÇÎïµÄθ°©¾«×¼ÖÎÁÆ£¬£¬£¬¸ÄÉÆθ°©»¼ÕßµÄÖÎÁÆЧ¹û¡£
TQB2210ÒÑÍê³ÉϵͳµÄÁÙ´²Ç°Ò©Àíѧ¡¢¡¢Ò©´ú¶¯Á¦Ñ§ºÍÇå¾²ÐÔÑéÖ¤£¬£¬£¬¶¾ÐÔ·çÏÕ¿É¿Ø¡£ÁÙ´²Ç°Êý¾ÝÏÔʾ£¬£¬£¬±¾Æ·¿É¼ÁÁ¿ÒÀÀµÐÔµØÏÔ×ÅÒÖÖÆθ°©SNU-16¡¢¡¢Î¸°©KATO ¢ó¡¢¡¢ÈéÏÙ°©MDA-MB-231/FGFR2¢ób¡¢¡¢Ê³¹ÜÁÛ״ϸ°û°©KYSE-180СÊóƤÏÂÒÆÖ²ÁöµÄÉú³¤¡£±¾Æ·ÒÖÁöЧ¹ûÓÅÓÚ»òÓëͬ°ÐµãÒ©ÎïBemarituzumabÏ൱£¬£¬£¬ÓëÅÉ°²ÆÕÀûµ¥¿¹×¢ÉäÒºÁªÓöÔθ°©KATO ¢óÂãСÊóƤÏÂÒÆÖ²ÁöµÄÁÆЧÏà½Ïµ¥Ò©ÓÐËùÌá¸ß£¬£¬£¬Î´À´ÓÐÍûÍØÕ¹ÁªºÏÖÎÁÆз¾¶¡£
ÏÖÔÚ£¬£¬£¬È«Çò¹æÄ£ÄÚ°üÀ¨TQB2210½öÓÐ4¿îͬ°ÐÏòÒ©Îï½øÈëÁÙ´²½×¶Î¡£×÷ΪȫÇòÉÙÊý½øÈëÁÙ´²½×¶ÎµÄͬÀàÒ©Î£¬£¬TQB2210ÒÀÍйú¼ÒÓÅ»¯ÉóÆÀÉóÅúÕþ²ßʵÏÖ¿ìËÙÍƽø¡£ÖйúÉúÎïÖÆÒ©½«³ÖÐøÉÉúÎï±ê¼ÇÎïÇý¶¯Ïµľ«×¼ÖÎÁÆÕ½ÂÔ£¬£¬£¬ÎªÌáÉý¶ñÐÔÖ×Áö»¼ÕßµÄÉúÑÄÂÊТ˳ʵÁ¦
²Î¿¼ÎÄÏ×£º£º£º
[1] Ahn, S, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Modern Pathology, 29(9), 1095–1103.
[2] Bane, A. L, et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Research and Treatment, 117(1), 183–191.
[3] Gordon, A, et al. Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments. OncoTargets and Therapy, 15, 1183–1196.
[4] Javle, M, et al.Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. The Lancet Gastroenterology & Hepatology, 6(10), 803–815.
[5] Wainberg ZA, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Oncology£¬£¬£¬2022, 23(11):1430-1440.
¡ø ÉÏÏ»¬¶¯Éó²é¸ü¶à
ÉùÃ÷£º£º£º
1.ÐÂΟåÖ¼ÔÚÔö½øÒ½Ò©ÐÅÏ¢µÄÏàͬºÍ½»Á÷£¬£¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬£¬£¬·Ç¹ã¸æÓÃ;¡£
2.±¾¹«Ë¾²î³ØÈκÎÒ©Æ·ºÍ/»ò˳Ӧ֢×÷ÍƼö¡£
3.±¾ÐÂΟåÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬£¬£¬²»¿ÉÒÔÈκη½Ê½È¡´úרҵµÄÒ½ÁÆÖ¸µ¼£¬£¬£¬Ò²²»Ó¦±»ÊÓΪÕïÁƽ¨Òé¡£ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£
Ç°Õ°ÐÔÉùÃ÷£º£º£º
±¾ÐÂΟåÖаüÀ¨Èô¸ÉÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬°üÀ¨Óйء¾TQB2210¡¿µÄÁÙ´²¿ª·¢ÍýÏë¡¢¡¢ÁÙ´²»ñÒæÓëÓÅÊƵÄÔ¤ÆÚ¡¢¡¢ÉÌÒµ»¯Õ¹Íû¡¢¡¢»¼ÕßÁÙ´²»ñÒæ¿ÉÄÜÐÔ£¬£¬£¬ÒÔ¼°Ç±ÔÚÉÌҵʱ»úµÈÉùÃ÷¡£“Ô¤ÆÚ”¡¢¡¢“ÏàÐÅ”¡¢¡¢“¼ÌÐø”¡¢¡¢“¿ÉÄÜ”¡¢¡¢“Ô¤¼Æ”¡¢¡¢“ÆÚÍû”¡¢¡¢“ÓÐÍû”¡¢¡¢“ÍýÏ딡¢¡¢“ÍýÏ딡¢¡¢“DZÔÚ”¡¢¡¢“Ô¤²â”¡¢¡¢“Ô¤¼Æ”¡¢¡¢“Ó¦¸Ã”¡¢¡¢“½«”¡¢¡¢“Ä┡¢¡¢“»á”ºÍÀàËƱí´ïÖ¼ÔÚʶ±ðÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬µ«²¢·ÇËùÓÐÇ°Õ°ÐÔ³ÂÊö¶¼°üÀ¨ÕâЩʶ±ð´Ê¡£ÕâЩǰհÐÔ³ÂÊöΪ¹«Ë¾»ùÓÚÄ¿½ñËùÕÆÎÕµÄÊý¾ÝºÍÐÅÏ¢Ëù×öµÄÔ¤²â»òÆÚÍû£¬£¬£¬¿ÉÄÜÒòÊܵ½Õþ²ß¡¢¡¢Ñз¢¡¢¡¢Êг¡¼°î¿ÏµµÈ²»È·¶¨ÒòËØ»ò·çÏÕµÄÓ°Ï죬£¬£¬¶øµ¼ÖÂÏÖʵЧ¹ûÓëÇ°Õ°ÐÔ³ÂÊöÓÐÖØ´ó²î±ð¡£ÇëÏÖÓлòDZÔÚµÄͶ×ÊÕßÉóÉ÷˼Á¿¿ÉÄܱ£´æµÄ·çÏÕ£¬£¬£¬²¢²»¿ÉÍêÈ«ÒÀÀµ±¾ÐÂΟåÖеÄÇ°Õ°ÐÔ³ÂÊö£¬£¬£¬¸ÃµÈ³ÂÊö°üÀ¨ÐÅÏ¢½ö¼°ÓÚ±¾ÐÂΟåÐû²¼µ±ÈÕ¡£³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬±¾¹«Ë¾ÎÞÒåÎñÒòÐÂÐÅÏ¢¡¢¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐζø¶Ô±¾ÐÂΟåÖÐÈκÎÇ°Õ°ÐÔ³ÂÊö¾ÙÐиüлòÐ޸ġ£